Tradestie Institutional Equity Comparison Engine
TLX vs APLS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
APLS Overall Edge
APLS Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Apellis Pharmaceuticals, Inc. Common Stock (APLS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, TLX trades at N/M Forward P/E with 6.2% operating margin (+22.3% YoY revenue) versus APLS at 46.3x Forward P/E and 9.9% operating margin (+60.9% YoY). In options structure, TLX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against APLS sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
APLS
TLX N/M vs APLS 46.3x Fwd P/E
Growth & Margin Winner
APLS
Op Margin 6.2% vs 9.9% ยท YoY +22.3% vs +60.9%
Momentum & Technical Winner
APLS
1Y -5.5% vs +134.2% ยท 52W Pos 40% vs 100%
Options & Structure Winner
APLS
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (<1st %ile IV)
TLX
NASDAQ
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.98
-2.65% 1D
Market Cap
$3.2B
1M Return
-15.95%
1Y Return
-5.52%
Forward P/E
N/M
Unified AI Score
46.4 / 100
HOLD
Tech 64.0
Fund 62.0
Flow 50.0
Mom 60.0
APLS
NASDAQ
Apellis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$41.03
-0.07% 1D
Market Cap
$5.3B
1M Return
+0.44%
1Y Return
+134.19%
Forward P/E
46.3x
Unified AI Score
60.2 / 100
BUY
Tech 40.0
Fund 52.0
Flow 67.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
TLX -5.52%
APLS +134.19%
Spread: +96.5 pp (APLS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
TLX TTM Op. Margin: 6.2%
APLS TTM Op. Margin: 9.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLX vs APLS. Trailing 12-month operating profitability (TLX 6.2% vs APLS 9.9%) and valuation multiples (TLX N/M vs APLS 46.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TLX | APLS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.2B | $5.3B | Larger Scale | APLS |
| Trailing P/E Ratio Valuation | 93.6x | 38.3x | Lower Multiple | APLS |
| Forward P/E Ratio Valuation | N/M | 46.3x | Lower Multiple | APLS |
| Revenue Growth (YoY) Growth | +22.3% | +60.9% | Higher Growth | APLS |
| Operating Margin (TTM) Profitability | 6.2% | 9.9% | Higher Margin | APLS |
| Net Profit Margin Profitability | 3.8% | 12.1% | Higher Margin | APLS |
| Return on Equity (ROE) Capital Efficiency | 7.4% | 46.0% | Higher ROE | APLS |
| 52-Week Range Position Momentum | 40% ($6โ$13) | 100% ($16โ$41) | Stronger Trend | APLS |
| Beta / 30D Volatility Risk Regime | 0.84ฮฒ ยท 62% Vol | 4.54ฮฒ ยท 2% Vol | Lower Realized Risk | APLS |
| Unified Institutional Score Composite Signal | 46.4 / 100 (HOLD) | 60.2 / 100 (BUY) | Higher Composite | APLS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full TLX vs APLS Buy Guide
TLX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
APLS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither TLX nor APLS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.